Abivax (NASDAQ:ABVX) Price Target Raised to $145.00

Abivax (NASDAQ:ABVX) had its price objective increased by Morgan Stanley from $101.00 to $145.00 in a research note issued to investors on Friday morning, Marketbeat reports. The firm currently has an overweight rating on the stock.

ABVX has been the subject of several other research reports. Truist Financial set a $140.00 target price on shares of Abivax in a research note on Monday, November 24th. BTIG Research boosted their price objective on shares of Abivax from $120.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday. Wall Street Zen lowered shares of Abivax from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Barclays initiated coverage on Abivax in a research note on Monday, October 13th. They issued an “overweight” rating and a $142.00 target price for the company. Finally, Piper Sandler reiterated an “overweight” rating and set a $142.00 price target on shares of Abivax in a research report on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Abivax presently has a consensus rating of “Moderate Buy” and a consensus target price of $135.08.

Abivax Trading Down 0.9%

Shares of NASDAQ ABVX opened at $114.40 on Friday. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. The stock’s 50 day moving average price is $120.17 and its two-hundred day moving average price is $85.64. Abivax has a 52-week low of $4.77 and a 52-week high of $148.83. The stock has a market capitalization of $8.92 billion, a P/E ratio of -27.37 and a beta of 0.68.

Abivax (NASDAQ:ABVX) last issued its earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The firm had revenue of ($4.92) million during the quarter. On average, analysts anticipate that Abivax will post -2.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Abivax

Several hedge funds and other institutional investors have recently made changes to their positions in the business. UBS Group AG grew its stake in shares of Abivax by 2,561.0% in the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after purchasing an additional 4,293,606 shares in the last quarter. Darwin Global Management Ltd. acquired a new stake in Abivax in the third quarter worth about $263,698,000. Paradigm Biocapital Advisors LP bought a new position in Abivax in the 3rd quarter valued at about $132,800,000. TCG Crossover Management LLC grew its position in Abivax by 17.4% in the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock valued at $603,774,000 after buying an additional 1,055,000 shares in the last quarter. Finally, Vestal Point Capital LP bought a new position in shares of Abivax in the third quarter valued at approximately $84,900,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.